Concepts (312)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
| Fibromyalgia | 28 | 2020 | 174 | 9.23 | Why? |
| Arthritis, Rheumatoid | 24 | 2021 | 2043 | 5.32 | Why? |
| Antirheumatic Agents | 25 | 2021 | 3023 | 4.19 | Why? |
| Rheumatic Diseases | 11 | 2021 | 2675 | 1.99 | Why? |
| Pain Measurement | 5 | 2018 | 533 | 1.43 | Why? |
| Rituximab | 4 | 2021 | 1096 | 1.09 | Why? |
| Tumor Necrosis Factor-alpha | 9 | 2019 | 2483 | 1.06 | Why? |
| Hyperbaric Oxygenation | 4 | 2019 | 268 | 1.01 | Why? |
| Autoimmune Diseases | 8 | 2021 | 1996 | 1.00 | Why? |
| Sympathetic Nervous System | 2 | 2017 | 111 | 0.90 | Why? |
| Biological Factors | 3 | 2021 | 276 | 0.89 | Why? |
| Spondylitis, Ankylosing | 3 | 2018 | 231 | 0.85 | Why? |
| Chronic Pain | 7 | 2019 | 736 | 0.81 | Why? |
| Rheumatoid Nodule | 1 | 2018 | 1 | 0.77 | Why? |
| Pregabalin | 1 | 2018 | 22 | 0.75 | Why? |
| Certolizumab Pegol | 1 | 2018 | 36 | 0.74 | Why? |
| Methotrexate | 4 | 2018 | 471 | 0.74 | Why? |
| Connective Tissue Diseases | 2 | 2017 | 187 | 0.71 | Why? |
| Dementia, Vascular | 1 | 2017 | 33 | 0.70 | Why? |
| Antidepressive Agents, Tricyclic | 1 | 2017 | 29 | 0.69 | Why? |
| Immunologic Surveillance | 1 | 2018 | 69 | 0.69 | Why? |
| Neuralgia | 1 | 2019 | 99 | 0.68 | Why? |
| Vagus Nerve | 1 | 2017 | 57 | 0.67 | Why? |
| Scleroderma, Systemic | 3 | 2019 | 583 | 0.65 | Why? |
| Glucuronidase | 1 | 2017 | 103 | 0.64 | Why? |
| Lung Diseases, Fungal | 1 | 2017 | 167 | 0.63 | Why? |
| Rheumatologists | 1 | 2020 | 346 | 0.62 | Why? |
| B-Lymphocyte Subsets | 1 | 2017 | 372 | 0.61 | Why? |
| Azetidines | 2 | 2020 | 722 | 0.60 | Why? |
| Sleep Wake Disorders | 2 | 2017 | 1463 | 0.60 | Why? |
| Pyrroles | 1 | 2018 | 292 | 0.59 | Why? |
| Calcium Channel Blockers | 1 | 2018 | 367 | 0.57 | Why? |
| Spondylarthritis | 1 | 2017 | 174 | 0.57 | Why? |
| Analgesics | 2 | 2018 | 451 | 0.57 | Why? |
| Drugs, Investigational | 1 | 2017 | 198 | 0.57 | Why? |
| Earthquakes | 1 | 2017 | 165 | 0.56 | Why? |
| Inflammatory Bowel Diseases | 4 | 2021 | 3209 | 0.53 | Why? |
| Central Nervous System | 1 | 2019 | 701 | 0.51 | Why? |
| Sulfonamides | 2 | 2020 | 1294 | 0.50 | Why? |
| Immune Tolerance | 1 | 2018 | 608 | 0.49 | Why? |
| Lung Diseases, Interstitial | 3 | 2019 | 1476 | 0.49 | Why? |
| T-Lymphocytes | 3 | 2021 | 6670 | 0.48 | Why? |
| Fatigue | 5 | 2020 | 2479 | 0.47 | Why? |
| Piperidines | 1 | 2018 | 795 | 0.46 | Why? |
| Antibodies, Monoclonal | 4 | 2017 | 8041 | 0.46 | Why? |
| Quality of Life | 5 | 2020 | 9820 | 0.45 | Why? |
| Vasculitis | 2 | 2017 | 691 | 0.45 | Why? |
| Virus Activation | 1 | 2016 | 480 | 0.44 | Why? |
| Arthritis, Psoriatic | 1 | 2017 | 625 | 0.43 | Why? |
| Physician's Role | 1 | 2020 | 853 | 0.43 | Why? |
| Pyrimidines | 1 | 2018 | 1557 | 0.41 | Why? |
| Immune System Diseases | 2 | 2021 | 410 | 0.40 | Why? |
| Patient Education as Topic | 2 | 2017 | 1476 | 0.39 | Why? |
| Fatigue Syndrome, Chronic | 2 | 2011 | 160 | 0.39 | Why? |
| Hepatitis B virus | 1 | 2016 | 882 | 0.36 | Why? |
| Disasters | 1 | 2017 | 760 | 0.36 | Why? |
| Pain Management | 3 | 2017 | 854 | 0.35 | Why? |
| Health Status | 3 | 2018 | 3259 | 0.34 | Why? |
| B-Lymphocytes | 3 | 2021 | 4418 | 0.34 | Why? |
| Humans | 85 | 2021 | 930598 | 0.32 | Why? |
| Cryoglobulinemia | 2 | 2019 | 144 | 0.32 | Why? |
| Lupus Erythematosus, Systemic | 1 | 2017 | 1380 | 0.31 | Why? |
| Central Nervous System Diseases | 1 | 2011 | 410 | 0.31 | Why? |
| Severity of Illness Index | 10 | 2020 | 48226 | 0.31 | Why? |
| Remission Induction | 3 | 2019 | 950 | 0.30 | Why? |
| Sjogren's Syndrome | 2 | 2019 | 284 | 0.30 | Why? |
| Drug Design | 1 | 2017 | 2627 | 0.29 | Why? |
| Hypotension, Orthostatic | 1 | 2005 | 55 | 0.29 | Why? |
| Respiratory Rate | 2 | 2020 | 691 | 0.28 | Why? |
| Biological Therapy | 2 | 2021 | 456 | 0.28 | Why? |
| Immunophenotyping | 3 | 2017 | 1290 | 0.27 | Why? |
| Immunotherapy | 1 | 2017 | 2421 | 0.26 | Why? |
| Immunocompromised Host | 1 | 2020 | 5150 | 0.26 | Why? |
| Antibodies, Monoclonal, Humanized | 5 | 2020 | 9335 | 0.26 | Why? |
| Purines | 2 | 2020 | 816 | 0.25 | Why? |
| Middle Aged | 31 | 2021 | 270681 | 0.25 | Why? |
| Immunosuppressive Agents | 2 | 2021 | 6331 | 0.24 | Why? |
| Syncope | 1 | 2005 | 238 | 0.24 | Why? |
| Pain | 4 | 2018 | 1084 | 0.24 | Why? |
| Anti-Inflammatory Agents | 2 | 2020 | 6153 | 0.23 | Why? |
| Infliximab | 4 | 2019 | 502 | 0.23 | Why? |
| Vaccines | 1 | 2021 | 3692 | 0.23 | Why? |
| Cytokines | 3 | 2020 | 15010 | 0.22 | Why? |
| Female | 32 | 2021 | 380317 | 0.20 | Why? |
| Neuromuscular Junction | 1 | 2019 | 18 | 0.20 | Why? |
| Lymphocyte Depletion | 1 | 2021 | 293 | 0.20 | Why? |
| Muscle Fatigue | 1 | 2019 | 25 | 0.20 | Why? |
| Adult | 24 | 2021 | 244371 | 0.19 | Why? |
| Treatment Outcome | 9 | 2019 | 51732 | 0.19 | Why? |
| Aged | 21 | 2021 | 215776 | 0.19 | Why? |
| Pain Clinics | 1 | 2018 | 30 | 0.19 | Why? |
| Autoimmunity | 2 | 2018 | 841 | 0.19 | Why? |
| CD27 Ligand | 1 | 2017 | 17 | 0.18 | Why? |
| Consensus Development Conferences as Topic | 1 | 2018 | 93 | 0.18 | Why? |
| Pyrazoles | 2 | 2020 | 1791 | 0.18 | Why? |
| Flow Cytometry | 2 | 2017 | 2393 | 0.18 | Why? |
| Peroneal Nerve | 1 | 2017 | 13 | 0.18 | Why? |
| Hypnosis | 1 | 2017 | 8 | 0.18 | Why? |
| Spondylarthropathies | 1 | 2019 | 163 | 0.18 | Why? |
| Hand Joints | 1 | 2017 | 31 | 0.18 | Why? |
| Anti-Citrullinated Protein Antibodies | 1 | 2017 | 40 | 0.18 | Why? |
| Male | 27 | 2021 | 367725 | 0.17 | Why? |
| Coccidioidomycosis | 1 | 2017 | 47 | 0.17 | Why? |
| Atherosclerosis | 2 | 2017 | 768 | 0.17 | Why? |
| Rheumatoid Factor | 1 | 2017 | 67 | 0.17 | Why? |
| Joints | 1 | 2018 | 97 | 0.17 | Why? |
| Adult Survivors of Child Adverse Events | 1 | 2017 | 27 | 0.17 | Why? |
| Catecholamines | 1 | 2017 | 66 | 0.17 | Why? |
| Spectrum Analysis | 1 | 2017 | 112 | 0.17 | Why? |
| Lymphocyte Count | 2 | 2021 | 4758 | 0.17 | Why? |
| Lymphoma, B-Cell | 1 | 2019 | 166 | 0.17 | Why? |
| Histoplasmosis | 1 | 2017 | 83 | 0.16 | Why? |
| Neuromuscular Agents | 1 | 2017 | 87 | 0.16 | Why? |
| Tomography, X-Ray Computed | 2 | 2020 | 25144 | 0.16 | Why? |
| Adalimumab | 2 | 2019 | 389 | 0.16 | Why? |
| Cryptococcosis | 1 | 2017 | 97 | 0.16 | Why? |
| Delayed-Action Preparations | 1 | 2018 | 291 | 0.16 | Why? |
| Systemic Vasculitis | 1 | 2017 | 74 | 0.16 | Why? |
| Drug Therapy, Combination | 4 | 2018 | 7268 | 0.16 | Why? |
| Janus Kinase 1 | 1 | 2018 | 254 | 0.16 | Why? |
| Vaccination | 5 | 2021 | 19050 | 0.16 | Why? |
| Cardiovascular Diseases | 2 | 2018 | 11497 | 0.16 | Why? |
| Acute Pain | 1 | 2017 | 73 | 0.16 | Why? |
| Interleukin-1 | 1 | 2020 | 438 | 0.16 | Why? |
| Macrophage Activation Syndrome | 1 | 2020 | 342 | 0.15 | Why? |
| Case-Control Studies | 4 | 2017 | 17671 | 0.15 | Why? |
| Oxygen | 2 | 2020 | 3715 | 0.15 | Why? |
| Arthralgia | 1 | 2017 | 173 | 0.15 | Why? |
| Biosimilar Pharmaceuticals | 1 | 2019 | 205 | 0.15 | Why? |
| Polysomnography | 1 | 2017 | 296 | 0.15 | Why? |
| Candidemia | 1 | 2020 | 353 | 0.15 | Why? |
| Neural Conduction | 1 | 2017 | 261 | 0.15 | Why? |
| Autonomic Nervous System | 1 | 2017 | 148 | 0.15 | Why? |
| Walk Test | 1 | 2018 | 461 | 0.15 | Why? |
| Breath Tests | 1 | 2019 | 338 | 0.15 | Why? |
| Blood Sedimentation | 1 | 2017 | 508 | 0.15 | Why? |
| Italy | 9 | 2020 | 38444 | 0.14 | Why? |
| Walking | 1 | 2018 | 442 | 0.13 | Why? |
| T-Lymphocytes, Helper-Inducer | 1 | 2017 | 497 | 0.13 | Why? |
| Homeostasis | 1 | 2017 | 582 | 0.13 | Why? |
| Disability Evaluation | 1 | 2017 | 671 | 0.13 | Why? |
| Surveys and Questionnaires | 7 | 2020 | 43792 | 0.13 | Why? |
| Exercise Tolerance | 1 | 2018 | 634 | 0.12 | Why? |
| Pneumonia, Pneumocystis | 1 | 2017 | 322 | 0.12 | Why? |
| Neoplasms | 2 | 2018 | 17251 | 0.12 | Why? |
| Pneumonia, Viral | 6 | 2020 | 243684 | 0.12 | Why? |
| Coronavirus Infections | 6 | 2020 | 253789 | 0.12 | Why? |
| Diagnosis, Differential | 3 | 2019 | 7220 | 0.12 | Why? |
| Epigenesis, Genetic | 1 | 2019 | 711 | 0.12 | Why? |
| Pulmonary Aspergillosis | 1 | 2017 | 408 | 0.12 | Why? |
| Financing, Government | 1 | 2017 | 434 | 0.12 | Why? |
| Synaptic Transmission | 1 | 2011 | 46 | 0.12 | Why? |
| Terminology as Topic | 1 | 2017 | 546 | 0.12 | Why? |
| Comorbidity | 5 | 2020 | 34796 | 0.12 | Why? |
| Antidepressive Agents | 1 | 2017 | 509 | 0.12 | Why? |
| Ultrasonography | 2 | 2019 | 4409 | 0.11 | Why? |
| Pain Perception | 1 | 2011 | 48 | 0.11 | Why? |
| Nitric Oxide | 1 | 2019 | 769 | 0.11 | Why? |
| Adaptive Immunity | 3 | 2019 | 2585 | 0.11 | Why? |
| Exercise Therapy | 2 | 2017 | 976 | 0.11 | Why? |
| Inflammasomes | 1 | 2018 | 710 | 0.11 | Why? |
| Fractures, Bone | 1 | 2017 | 487 | 0.11 | Why? |
| Opportunistic Infections | 1 | 2018 | 602 | 0.11 | Why? |
| Interferon-gamma | 1 | 2021 | 2711 | 0.11 | Why? |
| Overweight | 1 | 2017 | 916 | 0.11 | Why? |
| Kaplan-Meier Estimate | 2 | 2017 | 4260 | 0.11 | Why? |
| Registries | 4 | 2019 | 12327 | 0.10 | Why? |
| Logistic Models | 4 | 2017 | 9089 | 0.10 | Why? |
| Drug Industry | 1 | 2017 | 689 | 0.10 | Why? |
| Hypertension, Pulmonary | 1 | 2018 | 970 | 0.09 | Why? |
| Animals | 9 | 2019 | 78931 | 0.09 | Why? |
| Receptors, Interleukin-6 | 1 | 2017 | 1383 | 0.09 | Why? |
| Bipolar Disorder | 1 | 2017 | 744 | 0.09 | Why? |
| Biomarkers | 5 | 2019 | 23361 | 0.09 | Why? |
| Microbiota | 1 | 2019 | 1240 | 0.09 | Why? |
| Antipsychotic Agents | 1 | 2017 | 887 | 0.09 | Why? |
| Prognosis | 4 | 2020 | 32490 | 0.09 | Why? |
| ROC Curve | 1 | 2020 | 6024 | 0.09 | Why? |
| Electrocardiography | 2 | 2017 | 3957 | 0.09 | Why? |
| Immunity, Cellular | 1 | 2021 | 3614 | 0.09 | Why? |
| Depressive Disorder, Major | 1 | 2017 | 852 | 0.09 | Why? |
| Longitudinal Studies | 3 | 2019 | 9893 | 0.09 | Why? |
| Sleep | 2 | 2019 | 2695 | 0.09 | Why? |
| Proportional Hazards Models | 2 | 2017 | 6543 | 0.09 | Why? |
| Antimalarials | 1 | 2020 | 2505 | 0.09 | Why? |
| Prevalence | 5 | 2020 | 25773 | 0.08 | Why? |
| Risk Factors | 5 | 2020 | 71621 | 0.08 | Why? |
| Pressoreceptors | 1 | 2005 | 11 | 0.08 | Why? |
| Tilt-Table Test | 1 | 2005 | 20 | 0.08 | Why? |
| Disabled Persons | 1 | 2017 | 1152 | 0.08 | Why? |
| Pharmaceutical Preparations | 1 | 2021 | 1897 | 0.08 | Why? |
| Blood Pressure | 1 | 2017 | 2198 | 0.08 | Why? |
| Abatacept | 2 | 2017 | 192 | 0.07 | Why? |
| MicroRNAs | 1 | 2019 | 1787 | 0.07 | Why? |
| Cardiovascular Physiological Phenomena | 1 | 2005 | 70 | 0.07 | Why? |
| Retrospective Studies | 6 | 2021 | 105322 | 0.07 | Why? |
| Immunity, Innate | 3 | 2019 | 6570 | 0.07 | Why? |
| Chloroquine | 1 | 2020 | 3152 | 0.07 | Why? |
| Prospective Studies | 3 | 2019 | 43301 | 0.07 | Why? |
| Aged, 80 and over | 4 | 2020 | 88759 | 0.07 | Why? |
| Betacoronavirus | 5 | 2020 | 204454 | 0.07 | Why? |
| Body Mass Index | 1 | 2017 | 4306 | 0.07 | Why? |
| Resilience, Psychological | 1 | 2019 | 2329 | 0.07 | Why? |
| Inflammation | 3 | 2021 | 13255 | 0.07 | Why? |
| Follow-Up Studies | 2 | 2017 | 17020 | 0.07 | Why? |
| Radiography, Thoracic | 1 | 2020 | 5486 | 0.06 | Why? |
| Young Adult | 6 | 2021 | 93724 | 0.06 | Why? |
| Clinical Trials as Topic | 3 | 2018 | 7330 | 0.06 | Why? |
| Biological Products | 1 | 2017 | 2331 | 0.06 | Why? |
| Reference Values | 1 | 2005 | 795 | 0.06 | Why? |
| Pandemics | 8 | 2021 | 389249 | 0.06 | Why? |
| Referral and Consultation | 1 | 2018 | 4816 | 0.06 | Why? |
| Analgesics, Opioid | 1 | 2012 | 1070 | 0.06 | Why? |
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2012 | 1454 | 0.06 | Why? |
| Blood Pressure Determination | 1 | 2005 | 450 | 0.06 | Why? |
| Precision Medicine | 1 | 2011 | 1477 | 0.06 | Why? |
| Treatment Failure | 2 | 2018 | 2106 | 0.05 | Why? |
| C-Reactive Protein | 1 | 2017 | 7972 | 0.05 | Why? |
| Hypotrichosis | 1 | 2020 | 40 | 0.05 | Why? |
| Heart Diseases | 1 | 2017 | 3503 | 0.05 | Why? |
| Skin Diseases, Genetic | 1 | 2020 | 65 | 0.05 | Why? |
| Phosphotransferases | 1 | 2019 | 16 | 0.05 | Why? |
| Isometric Contraction | 1 | 2019 | 19 | 0.05 | Why? |
| Hydroxychloroquine | 2 | 2021 | 12447 | 0.05 | Why? |
| Polymorphism, Genetic | 1 | 2007 | 1074 | 0.05 | Why? |
| Muscle Contraction | 1 | 2019 | 60 | 0.05 | Why? |
| Central Nervous System Sensitization | 1 | 2017 | 20 | 0.04 | Why? |
| Colitis | 1 | 2021 | 266 | 0.04 | Why? |
| Glomerulonephritis | 1 | 2021 | 226 | 0.04 | Why? |
| Salivary Glands | 1 | 2019 | 122 | 0.04 | Why? |
| Uveitis | 1 | 2021 | 233 | 0.04 | Why? |
| Etanercept | 1 | 2019 | 162 | 0.04 | Why? |
| Cryoglobulins | 1 | 2017 | 51 | 0.04 | Why? |
| Calcinosis | 1 | 2020 | 240 | 0.04 | Why? |
| Electromyography | 1 | 2019 | 278 | 0.04 | Why? |
| Expert Testimony | 1 | 2021 | 658 | 0.04 | Why? |
| Hemodynamics | 1 | 2005 | 1562 | 0.04 | Why? |
| Time Factors | 2 | 2017 | 31397 | 0.04 | Why? |
| Carcinogenesis | 1 | 2019 | 236 | 0.04 | Why? |
| Diagnostic and Statistical Manual of Mental Disorders | 1 | 2017 | 184 | 0.04 | Why? |
| Obesity | 1 | 2017 | 7388 | 0.04 | Why? |
| Severe Acute Respiratory Syndrome | 1 | 2020 | 12361 | 0.04 | Why? |
| Heart Valve Diseases | 1 | 2020 | 355 | 0.04 | Why? |
| United States | 3 | 2017 | 46150 | 0.04 | Why? |
| Adolescent | 4 | 2021 | 86841 | 0.04 | Why? |
| Disease Outbreaks | 2 | 2021 | 27595 | 0.04 | Why? |
| Odds Ratio | 2 | 2017 | 5861 | 0.04 | Why? |
| Exhalation | 1 | 2019 | 441 | 0.04 | Why? |
| Autoantigens | 1 | 2017 | 388 | 0.04 | Why? |
| Triglycerides | 1 | 2017 | 478 | 0.03 | Why? |
| Global Health | 1 | 2018 | 13911 | 0.03 | Why? |
| Cardiorespiratory Fitness | 1 | 2018 | 313 | 0.03 | Why? |
| Chronic Disease | 2 | 2019 | 5139 | 0.03 | Why? |
| Syndrome | 1 | 2019 | 1310 | 0.03 | Why? |
| CD4 Lymphocyte Count | 1 | 2019 | 1517 | 0.03 | Why? |
| Complement System Proteins | 1 | 2017 | 380 | 0.03 | Why? |
| Cholesterol | 1 | 2017 | 660 | 0.03 | Why? |
| Wound Healing | 1 | 2017 | 424 | 0.03 | Why? |
| Interleukin-1beta | 1 | 2018 | 992 | 0.03 | Why? |
| China | 1 | 2020 | 50654 | 0.03 | Why? |
| Dysbiosis | 1 | 2019 | 685 | 0.03 | Why? |
| Th1 Cells | 1 | 2019 | 1228 | 0.03 | Why? |
| Predictive Value of Tests | 2 | 2018 | 9537 | 0.03 | Why? |
| Diagnostic Errors | 1 | 2019 | 865 | 0.03 | Why? |
| Europe | 2 | 2021 | 12702 | 0.03 | Why? |
| Muscle, Skeletal | 1 | 2019 | 915 | 0.03 | Why? |
| Lung | 1 | 2020 | 31049 | 0.03 | Why? |
| Infection Control | 1 | 2020 | 23131 | 0.03 | Why? |
| Scotland | 1 | 2015 | 1119 | 0.03 | Why? |
| Disease Progression | 2 | 2020 | 13580 | 0.02 | Why? |
| Metabolic Syndrome | 1 | 2017 | 810 | 0.02 | Why? |
| Genetic Predisposition to Disease | 2 | 2019 | 4027 | 0.02 | Why? |
| Antibodies, Viral | 1 | 2021 | 51949 | 0.02 | Why? |
| Medication Adherence | 1 | 2018 | 1270 | 0.02 | Why? |
| Lung Diseases | 1 | 2021 | 2361 | 0.02 | Why? |
| Incidence | 2 | 2021 | 25622 | 0.02 | Why? |
| Workflow | 1 | 2017 | 2373 | 0.02 | Why? |
| Rheumatology | 1 | 2017 | 1213 | 0.02 | Why? |
| Emotions | 1 | 2019 | 2418 | 0.02 | Why? |
| Orthopedic Procedures | 1 | 2017 | 1231 | 0.02 | Why? |
| Autoantibodies | 1 | 2017 | 2094 | 0.02 | Why? |
| Sciatica | 1 | 2005 | 6 | 0.02 | Why? |
| Multivariate Analysis | 1 | 2017 | 5440 | 0.02 | Why? |
| Intestinal Polyps | 1 | 2005 | 11 | 0.02 | Why? |
| Orthopedics | 1 | 2017 | 1279 | 0.02 | Why? |
| Inflammation Mediators | 1 | 2017 | 2654 | 0.02 | Why? |
| Hepatitis, Alcoholic | 1 | 2005 | 61 | 0.02 | Why? |
| Quality Improvement | 1 | 2017 | 2435 | 0.02 | Why? |
| Skin Diseases | 1 | 2021 | 2509 | 0.02 | Why? |
| Wounds and Injuries | 1 | 2017 | 1708 | 0.02 | Why? |
| Canada | 1 | 2017 | 6018 | 0.02 | Why? |
| Laboratories | 1 | 2017 | 2858 | 0.02 | Why? |
| Evidence-Based Medicine | 1 | 2017 | 3228 | 0.02 | Why? |
| Australia | 1 | 2017 | 6306 | 0.02 | Why? |
| Blood Glucose | 1 | 2017 | 3642 | 0.02 | Why? |
| Interleukin-6 | 1 | 2020 | 7522 | 0.01 | Why? |
| Reproducibility of Results | 1 | 2018 | 11304 | 0.01 | Why? |
| Risk Assessment | 1 | 2005 | 25439 | 0.01 | Why? |
| Graft vs Host Disease | 1 | 2005 | 501 | 0.01 | Why? |
| Child | 2 | 2021 | 70012 | 0.01 | Why? |
| Infant, Newborn | 1 | 2021 | 23105 | 0.01 | Why? |
| Adrenal Cortex Hormones | 1 | 2017 | 6537 | 0.01 | Why? |
| Disease Management | 1 | 2017 | 6841 | 0.01 | Why? |
| Mice | 1 | 2019 | 21357 | 0.01 | Why? |
| Diabetes Mellitus | 1 | 2021 | 8207 | 0.01 | Why? |
| Cross-Sectional Studies | 2 | 2017 | 53120 | 0.01 | Why? |
| Infant | 1 | 2021 | 30274 | 0.01 | Why? |
| United Kingdom | 1 | 2017 | 18046 | 0.01 | Why? |
| Child, Preschool | 1 | 2021 | 36283 | 0.01 | Why? |
| SARS Virus | 1 | 2020 | 13021 | 0.01 | Why? |
| Diabetes Mellitus, Type 2 | 1 | 2017 | 6166 | 0.01 | Why? |
| Hypertension | 1 | 2017 | 8895 | 0.01 | Why? |